Cantor Fitzgerald analyst Brandon Folkes maintained a Buy rating on Collegium Pharmaceutical (COLL) today and set a price target of $35. The company’s shares closed yesterday at $15.65, close to its 52-week low of $13.10.
Folkes noted:
“We expect upwards earnings revisions to levels not reflected in FactSet consensus to drive COLL shares higher. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $35 price target. The Disclosure Section may be found on pages 5 – 6.Valuation We use a blend of DCF and EV/EBITDA to arrive at our $35 price target.”
According to TipRanks.com, Folkes is a 2-star analyst with an average return of 0.4% and a 39.1% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and ANI Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Collegium Pharmaceutical with a $32.67 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $28.91 and a one-year low of $13.10. Currently, Collegium Pharmaceutical has an average volume of 450.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases.
